1944 - Tolerability and Safety of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Infants and Older Children in Global Studies

Co-Author(s)

• LF

  Laurence Flint, MD

  Pfizer Inc
  Pearl River, New York, United States

Presenting Author(s)

• 

  Kathleen McElwee, MD, MDH (she/her/hers)

  Director, Vaccine Clinical Research and Development
  Pfizer Inc
  Collegeville, PA, United States

  Slides

Co-Author(s)

• GO

  G. Laissa Ouedraogo, MD

  Pfizer Inc
  Collegeville, Pennsylvania, United States
• NT

  Noor Tamimi, MD

  Pfizer Inc
  Collegeville, Pennsylvania, United States
• MK

  Mary J. Kline, MD (she/her/hers)

  Associate Director, Vaccine Research and Development
  Pfizer Inc
  Collegeville, Pennsylvania, United States
• 

  Kimberly J. Center, M.D.

  Senior Director
  Pfizer
  Collegeville, Pennsylvania, United States
• AT

  Allison Thompson, MD

  Dr
  Pfizer Inc
  Pearl River, New York, United States
• Rd

  Richard de Solom, MBBS

  Pfizer Australia
  Sydney, New South Wales, Australia
• MY

  Masako Yamaji, MS

  Pfizer R&D Japan
  Tokyo, Tokyo, Japan
• JT

  James Trammel, MS

  Mr
  Pfizer Inc
  Collegeville, Pennsylvania, United States
• LL

  Lanyu Lei, PhD

  Pfizer Inc
  Collegeville, Pennsylvania, United States
• YP

  Yahong Peng, PhD

  Sr Director, Biostatistics
  Pfizer Inc
  Collegeville, Pennsylvania, United States
• 

  William C. Gruber, MD

  SVP
  Pfizer
  Pearl River, New York, United States
• DS

  Daniel Scott, MD

  Vice President
  Pfizer
  Collegeville, Pennsylvania, United States
• WW

  Wendy Watson, MD

  Senior Director
  Pfizer Vaccine Research and Development
  Collegeville, Pennsylvania, United States